截至2025年8月20日收盘，乐心医疗(300562)报收于16.44元，下跌0.18%，换手率7.2%，成交量11.65万 手，成交额1.9亿元。 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 交易信息汇总：8月20日，乐心医疗主力资金净流出936.86万元，游资资金净流出544.52万元，而 散户资金净流入1481.38万元。 公司公告汇总：乐心医疗发布2025年半年度权益分派实施公告，将以217289788股为基数，向全体 股东每10股派发现金红利1.30元（含税），股权登记日为2025年8月25日，除权除息日为2025年8 月26日。 8月20日，乐心医疗的资金流向情况如下：主力资金净流出936.86万元；游资资金净流出544.52万元；散 户资金净流入1481.38万元。 公司公告汇总 广东乐心医疗电子股份有限公司发布了2025年半年度权益分派实施公告。公告指出，公司将以 217289788股为基数，向全体股东每10股派发现金红利1.30元（含税），合计派发现金股利28247672.44 元。此次分红不送红股 ...

乐心医疗 2025 年公 证券代码：300562 证券简称：乐心医疗 公告编号：2025-088 广东乐心医疗电子股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年半年度权益分派方案为：以 217,289,788 股为基数，向全体股东 每 10 股派发现金人民币 1.30 元（含税），2025 年半年度拟分配现金股利合计人 民币 28,247,672.44 元。不送红股，不以资本公积转增股本；剩余未分配利润结 转至以后年度。若本次权益分配方案公告后至实施前，公司因股权激励行权、股 份回购等原因导致股本总额发生变化的，将按照分配比例不变的原则调整分配总 额。 注：根据相关规定，回购专户中的股份不得参与权益分派，目前公司回购专户持有公司 股份 912,200 股。因此，本次利润分配预案的股本基数 217,289,788 股 = 公司目前总股本 218,201,988 股－回购专户股份数量 912,200 股；下同。 乐心医疗 2025 年公 1、2025 年 4 月 18 日，公司召开 2 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].

Core Viewpoint - Le Xin Medical has shown significant improvement in profitability and cash flow in the first half of 2025, with positive developments in AI digital chronic disease management [1][2]. Financial Performance - In the first half of 2025, Le Xin Medical achieved operating revenue of 521 million yuan, a year-on-year increase of 4.57% [1]. - The net profit attributable to shareholders reached 42.29 million yuan, up 21.35% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 38.07 million yuan, reflecting a year-on-year growth of 17.57% [1]. - The net cash flow from operating activities increased by 46.80%, amounting to 48.25 million yuan [1]. Business Development - The company is building a comprehensive health management ecosystem based on "hardware + data + AI + services" [1]. - In the consumer medical device sector, Le Xin Medical continues to expand its product range, including electronic blood pressure monitors, body fat scales, blood glucose meters, and smart wristbands, while collaborating with international brands like Braun and Philips [1]. Remote Health Management - Le Xin Medical's remote health management (RPM) sector is steadily developing, with ongoing services for key clients such as Teladoc and Livongo [2]. - The company has made substantial progress in AI digital chronic disease management, particularly in cardiovascular disease risk screening and remote ECG services, establishing a complete technical chain from data collection to AI intervention [2]. Research and Development - In the first half of 2025, Le Xin Medical continued to invest in R&D for smart rings, multi-lead ECG machines, and remote blood glucose meters, aiming for a diversified and comprehensive health monitoring scenario [2]. - The company has achieved technical milestones in AI algorithms for chronic disease intervention, focusing on cardiovascular models, CMR image generation, and atrial fibrillation screening [2]. Shareholder Returns - The company proposed a mid-term profit distribution plan, intending to distribute a cash dividend of 1.30 yuan (tax included) for every 10 shares, with a total expected dividend of approximately 28.25 million yuan [2]. Future Outlook - Le Xin Medical aims to leverage its synergies in smart hardware, data integration, and AI algorithms to expand market coverage and solidify its dual-driven business development model of "smart health + medical services" [2].

Core Viewpoint - 乐心医疗 reported a revenue of 521 million yuan in the first half of 2025, representing a year-on-year growth of 4.57%, and a net profit attributable to shareholders of 42.29 million yuan, up 21.35% year-on-year, alongside a cash dividend proposal of 1.3 yuan per 10 shares [1] Group 1: Financial Performance - The company achieved a revenue of 521 million yuan, marking a 4.57% increase compared to the previous year [1] - The net profit attributable to shareholders reached 42.29 million yuan, reflecting a year-on-year growth of 21.35% [1] - A cash dividend of 1.3 yuan per 10 shares is proposed for all shareholders [1] Group 2: Product Development and Innovation - The company has extended its product layout, successfully advancing the smart ring project, which integrates multiple monitoring functions such as heart rate, blood oxygen, sleep, and atrial fibrillation [1] - High-end differentiated products like the auscultation blood pressure monitor and ECG blood pressure monitor are progressing well [1] - Several forward-looking products are in the pre-research phase, and high-end customized projects for multi-modal blood testing have made phased progress [1][2] Group 3: Technological Advancements - The company has deepened its algorithm barriers, completing local deployment of PPG diagnosis, PPG-ECG fusion algorithms, and ECG-CMR mapping algorithms, enhancing the controllability and stability of core algorithms [2] - Multi-sensor and multi-hardware device integration technology has been developed to optimize data collection, improving the accuracy of physiological monitoring [2] - Efforts to address power consumption challenges include architecture optimization and low-power technology development, leading to reduced standby and operational power consumption [2] Group 4: Customer Expansion and Market Presence - The company has made significant progress in key new projects, strengthening long-term partnerships with major clients while expanding its customer base among medium-sized digital chronic disease management service providers [3] - In international markets, the company focuses on local certification of products and platforms in Europe and the Middle East, while enhancing brand exposure in emerging markets through various exhibitions [3] - Active participation in major domestic and international medical exhibitions has increased the brand's visibility and influence globally [3]

据证券之星公开数据整理，近期乐心医疗（300562）发布2025年中报。截至本报告期末，公司营业总收 入5.21亿元，同比上升4.57%，归母净利润4229.04万元，同比上升21.35%。按单季度数据看，第二季度 营业总收入2.48亿元，同比下降0.74%，第二季度归母净利润1934.84万元，同比下降8.67%。本报告期 乐心医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达330.81%。 业务评价：公司去年的ROIC为4.83%，近年资本回报率不强。公司业绩具有周期性。去年的净利率为 5.91%，算上全部成本后，公司产品或服务的附加值一般。从历史年报数据统计来看，公司上市以来中 位数ROIC为6.02%，投资回报一般，其中最惨年份2022年的ROIC为-3.85%，投资回报极差。公司历史 上的财报相对一般（注：公司上市时间不满10年，上市时间越长财务均分参考意义越大。），公司上市 来已有年报8份，亏损年份1次，需要仔细研究下有无特殊原因。 偿债能力：公司现金资产非常健康。 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | ...

2025年8月16日，乐心医疗(300562.SZ)发布2025年中报。 公司营业总收入为5.21亿元。归母净利润为4229.04万元。经营活动现金净流入为4825.39万元。 公司最新资产负债率为33.31%。 公司摊薄每股收益为0.19元。 公司最新总资产周转率为0.35次。最新存货周转率为4.06次。 公司股东户数为2.57万户，前十大股东持股数量为7808.49万股，占总股本比例为35.89%，前十大股东 持股情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | J | 潘伟潮 | 30.70% | | 2 | 潘志刚 | 0.92% | | 3 | 孙浩 | 0.73% | | 4 | *东乐心医疗电子股份有限公司-2024年员工持股计划 | 0.69% | | 5 | 中国银行股份有限公司-招商量化精选股票型发起式证券投资基金 | 0.60% | | 6 | BARCLAYS BANK PLC | 0.56% | | 7 | 中国建设银行股份有限公司-圆信永丰聚优股票型证券投资基金 | 0.45% | | 8 | 瞿新民 | 0.44% | | 9 | ...

格隆汇8月15日丨乐心医疗(300562.SZ)公布2025年半年度报告，上半年公司实现营业收入5.21亿元，同 比增长4.57%；归属于上市公司股东的净利润4229.04万元，同比增长21.35%；归属于上市公司股东的扣 除非经常性损益的净利润3807.09万元，同比增长17.57%；基本每股收益0.1945元；拟向全体股东每10 股派发现金红利1.30元(含税)。 ...

乐心医疗(300562.SZ)公告称，公司上半年实现营收5.21亿元，同比增长4.57%；归属于上市公司股东的 净利润为4229.04万元，同比增长21.35%。公司拟向全体股东每10股派发现金红利1.3元（含税）。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

人民财讯8月15日电，乐心医疗（300562）8月15日晚间披露2025年半年报，公司上半年实现营收5.21亿 元，同比增长4.57%；归属于上市公司股东的净利润为4229.04万元，同比增长21.35%。公司拟向全体股 东每10股派发现金红利1.3元(含税)。 ...